<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2013040612918N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2014-09-08</date_registration>
      <primary_sponsor>Faculty of medicine of Tehran University of Medical Siences</primary_sponsor>
      <public_title>The effect of vitamin C injection before surgery in patient's pain control</public_title>
      <acronym></acronym>
      <scientific_title>The effect of 2 grams vitamin C single dose IV injection compare with 20 ml of normal saline injection  half an hour before laparoscopic cholecystectomy in pain and the patient's postoperative total opium usage in Shariati Hospital in 1393</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2014-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>110</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/12909</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Cholecystitis. Condition 2: post op use of opium. Condition 3: postoperative  pain. Condition 4: post operative nausea and vomiting. Condition 5: surgical wound infection. Condition 6: calculus of gallbladder. Condition 7: calculus of ballblader without cholecystitis. Condition 8: calculus of gallbladder with other cholecystitis.</hc_freetext>
      <i_freetext>Intervention 1: The intervention is one single dose of 2 grams of vitamin c of Osve pharmacological factory that made in  IRAN ,that is equal to 4 vials of vitamin c that diluted with normal saline up to 20 cc and intravenously injected  in the operation room after general anesthesia. Intervention 2: In the control group 20 cc normal saline injected intravenously after general anesthesia before surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sara Emami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>North Karegar street, Jalal Al Ahmad Highway</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 8490 2450</telephone>
        <email>s_emami@razi.tums.ac.ir</email>
        <affiliation>Dr Shariati Hospital, surgery ward</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Zhamak Khorgami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>North Karegar street, Jalal Al Ahmad tree way street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8490 2450</telephone>
        <email>khorgami@gmail.com</email>
        <affiliation>Dr Shariati hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion Criteria: Patients who are considered for laparoscopic cholecystectomy (Laparoscopic surgery due to biliary Colic or cholecyctitis)&#13;
 Exclusion Criteria: Patients who are allergic to Narcotics or abusing drugs will be excluded from the study. In the case of necessity for simultaneous surgery, the patient will be excluded from the study. During 24- hour follow-up, Naloxone will be provided for the patients, and if patients’ respiratory rate drops below 12, PCA will be stopped and patient will be excluded from the study.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>k81.9</hc_code>
      <hc_code>y45.0</hc_code>
      <hc_code>r 10</hc_code>
      <hc_code>r11</hc_code>
      <hc_code>t81.4</hc_code>
      <hc_code>k80.0</hc_code>
      <hc_code>k80.2</hc_code>
      <hc_code>k80.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cholecyctitis unspecified</hc_keyword>
      <hc_keyword>Opioids and related analgesics</hc_keyword>
      <hc_keyword>abdominal and pelvic pain</hc_keyword>
      <hc_keyword>Nausea and vomiting</hc_keyword>
      <hc_keyword>Infection following a procedure, not elsewhere classified</hc_keyword>
      <hc_keyword>calculus of gallbladder with acute cholecystitis</hc_keyword>
      <hc_keyword>calculus of ballblader without cholecystitis</hc_keyword>
      <hc_keyword>calculus of gallbladder with other cholecystitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The intervention is one single dose of 2 grams of vitamin c of Osve pharmacological factory that made in  IRAN ,that is equal to 4 vials of vitamin c that diluted with normal saline up to 20 cc and intravenously injected  in the operation room after general anesthesia</i_keyword>
      <i_keyword>In the control group 20 cc normal saline injected intravenously after general anesthesia before surgery</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Amount of opium used. Timepoint: 6 and 24 hours after surgery. Method of measurement: patient controlled anesthesia.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Nausea and vomiting. Timepoint: every 6 hours. Method of measurement: visual analoge scale.</sec_outcome>
      <sec_outcome>Wound infection. Timepoint: after 7 days. Method of measurement: physical examination.</sec_outcome>
      <sec_outcome>Patient satisfaction. Timepoint: after 24 hours. Method of measurement: sf 12 questionair.</sec_outcome>
      <sec_outcome>Urinary retention. Timepoint: during 24 hours. Method of measurement: examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Faculty of medicine of Tehran University of Medical Siences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-03-31</approval_date>
        <contact_name>Research and technology center of Tehran University of Medical Siences</contact_name>
        <contact_address>Poorsina street, faculty of medicin of Tehran University of Medical Siences Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
